EGFR and non-small cell lung carcinoma: In this regard, it was reported that, in advanced EGFR-positive NSCLC, tumors harboring concurrent TP53 or RB1 mutations showed a higher risk of histologic transformation and inferior sensitivity to EGFR-TKI [16,17].